-
Product Insights
New![]()
Net Present Value Model: Shionogi & Co Ltd’s Olorofim
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Shionogi & Co Ltd’s Sivopixant
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Shionogi & Co Ltd’s Zatolmilast
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Product Insights
New![]()
Net Present Value Model: Shionogi & Co Ltd’s Resiniferatoxin
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Shionogi & Co Ltd’s S-488210
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Shionogi & Co Ltd’s S-588410
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Company Profile
![]()
Shionogi Inc – Company Profile
Shionogi Inc (Shionogi), a subsidiary of Shionogi & Co., Ltd, is a pharmaceutical company that develops and commercializes pharmaceutical products to address unmet medical needs. The company offers a wide range of branded prescription products to treat chronic diseases. It markets products for various therapeutic areas such as pain, anti-infectives, women's health, pediatrics, cardiovascular, and others. Shionogi offers its products in various formulations such as tablets, oral suspensions (solutions), lotions, capsules, chewable tablets, and injections. Some of the company’s key...
Add to Basket -
Company Profile
![]()
Shionogi & Co Ltd – Company Profile
Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for the therapeutic areas including metabolic disorders, infectious diseases, pain/central nervous system (CNS), and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of...
Add to Basket -
Product Insights
New![]()
Net Present Value Model: Kronos Bio Inc’s LANRA
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: ADC Therapeutics SA’s Camidanlumab tesirine
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Ionis Pharmaceuticals Inc’s Sapablursen Sodium
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Neurocrine Biosciences Inc’s Crinecerfont
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Neurocrine Biosciences Inc's Crinecerfont Drug Details: Crinecerfont (NBI-74788) is under development for the treatment of congenital adrenal hyperplasia. The drug candidate target corticotropin-releasing factor...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – S-309309 in Obesity
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. S-309309 in Obesity Drug Details: S-309309 is under development for the treatment of obesity. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SVT-15652 in Otitis Externa
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SVT-15652 in Otitis Externa Drug Details: SVT-15652 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PT-886 in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PT-886 in Gastric Cancer Drug Details:PT-886 is under development for the treatment of metastatic gastric adenocarcinoma, ...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MDR-103 in Kidney Transplant Rejection
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MDR-103 in Kidney Transplant Rejection Drug Details:MDR-103 is under development for the treatment of kidney transplant...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Paroxysmal Nocturnal Hemoglobinuria in Paroxysmal Nocturnal Hemoglobinuria
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Paroxysmal Nocturnal Hemoglobinuria in Paroxysmal Nocturnal Hemoglobinuria Drug Details: Monoclonal antibody is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Golcadomide in Non-Hodgkin Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Golcadomide in Non-Hodgkin LymphomaDrug Details:CC-99282 is under development for the treatment of relapsed or refractory, non-Hodgkin...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Redasemtide Trifluoroacetate in Acute Ischemic Stroke
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Redasemtide Trifluoroacetate in Acute Ischemic StrokeDrug Details:Redasemtide trifluoroacetate is under development for the treatment of acute...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Izalontamab in Laryngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Izalontamab in Laryngeal Cancer Drug Details: SIB-001 is under development for the treatment of squamous...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.